You are here: Industry Insights > Neurocrine Biosciences

News List

Takeda licences psychiatry programmes to Neurocrine Biosciences pharmaceutical-technology
June 18, 2020
Takeda Pharmaceutical has collaborated with US-based Neurocrine Biosciences for the development and commercialisation of therapeutic compounds in its early-to-mid-stage psychiatry pipeline.
Neurocrine Biosciences Exercises Option to License Rare Pediatric Epilepsy Treatment americanpharmaceuticalreview
May 18, 2020
Neurocrine Biosciences and Idorsia announced, following Investigational New Drug (IND) application acceptance by the U.S. Food and Drug Administration (FDA), Neurocrine Biosciences has exercised its option ...
Neurocrine Biosciences Announces NDA Acceptance of Parkinson's Treatment americanpharmaceuticalreview
July 12, 2019
Neurocrine Biosciences announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for opicapone, a novel, once-daily, oral, selective catechol-O-methyltransferase (COMT) inhibitor as ...